List of Excipients in Branded Drug EPSOLAY

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Galderma Laboratories LP	EPSOLAY	benzoyl peroxide	0299-5890	ANHYDROUS CITRIC ACID	2028-02-03
Galderma Laboratories LP	EPSOLAY	benzoyl peroxide	0299-5890	CETRIMONIUM CHLORIDE	2028-02-03
Galderma Laboratories LP	EPSOLAY	benzoyl peroxide	0299-5890	CETYL ALCOHOL	2028-02-03
Galderma Laboratories LP	EPSOLAY	benzoyl peroxide	0299-5890	CYCLOMETHICONE	2028-02-03
Galderma Laboratories LP	EPSOLAY	benzoyl peroxide	0299-5890	EDETATE DISODIUM	2028-02-03

Epsolay Excipient Strategy and Commercial Opportunities

Last updated: August 13, 2026

Epsolay is a prescription topical cream containing 5% benzoyl peroxide for the treatment of inflammatory lesions of rosacea in adults. Its commercial differentiation depends on controlled delivery of benzoyl peroxide, improved tolerability, and a formulation that maintains stability despite the active ingredient’s oxidative reactivity. The principal excipient opportunity is to develop comparable encapsulation, dispersion, stabilization, and sensory-performance systems for topical dermatology products.

What is Epsolay and how does its formulation work?

Epsolay is Galderma’s benzoyl peroxide 5% cream approved by the U.S. Food and Drug Administration in April 2022 for inflammatory lesions of rosacea in adults.[1] The product uses a proprietary encapsulation approach designed to reduce direct exposure of the skin to benzoyl peroxide immediately after application.

The formulation contains:

Component	Function in the formulation
Benzoyl peroxide, 5%	Active antimicrobial and anti-inflammatory ingredient
Acrylamide/sodium acryloyldimethyltaurate copolymer	Rheology modifier, suspension stabilizer, and emulsion-support excipient
Isohexadecane	Emollient and oil-phase vehicle
Polysorbate 80	Surfactant and dispersion aid
Sodium benzoate	Preservative
Purified water	Continuous aqueous phase

The FDA-approved label identifies benzoyl peroxide as the active ingredient and lists the remaining components as inactive ingredients.[2] Public product materials describe the benzoyl peroxide as encapsulated in silica microspheres. The microsphere system is central to Epsolay’s differentiation because conventional benzoyl peroxide products can produce dryness, erythema, scaling, burning, and irritation.

What excipient strategy protects Epsolay’s commercial position?

Epsolay’s excipient strategy is based on delivery control rather than pharmacological novelty. The product uses formulation architecture to modify how benzoyl peroxide contacts the skin.

Encapsulation reduces initial benzoyl peroxide exposure

Benzoyl peroxide is effective but chemically reactive. In conventional creams and gels, the active is dispersed directly through the vehicle. Epsolay’s encapsulated approach separates benzoyl peroxide from the surrounding formulation and releases it progressively after application.

This can support four commercial claims:

1. Improved tolerability compared with unencapsulated benzoyl peroxide.
2. Lower immediate irritation potential.
3. More controlled deposition on the skin.
4. Differentiation from generic benzoyl peroxide creams and gels.

The value of the excipient system is therefore linked to measured release, particle integrity, active uniformity, skin deposition, irritation testing, and clinical outcomes.

Silica microspheres create a technical barrier to substitution

A competitor cannot necessarily reproduce Epsolay by replacing one excipient in a conventional benzoyl peroxide cream. A comparable product may require control of:

• Microsphere particle-size distribution.
• Benzoyl peroxide loading.
• Encapsulation efficiency.
• Surface chemistry.
• Porosity and release rate.
• Moisture content.
• Oxidative stability.
• Mechanical rupture during manufacturing and application.
• Compatibility with preservatives, surfactants, and emollients.

These parameters create a manufacturing and development barrier. They also provide potential claim scope for composition, process, particle morphology, release behavior, and therapeutic use patents.

What formulation patents protect Epsolay?

Epsolay’s commercial protection is expected to rely on formulation and delivery patents rather than on long-term exclusivity for benzoyl peroxide itself. Benzoyl peroxide is an established active ingredient with extensive prior art in acne and rosacea products.

The relevant intellectual-property categories are:

Patent category	Commercial relevance
Encapsulated benzoyl peroxide compositions	Protects the active-excipient architecture
Silica microsphere systems	Protects particle structure and delivery mechanism
Controlled-release topical formulations	Protects release profiles and skin delivery
Manufacturing methods	Protects loading, coating, drying, and blending processes
Rosacea treatment methods	Protects use of the formulation for inflammatory lesions
Stability and packaging systems	Protects control of peroxide degradation and container interaction

The strongest claims would generally be those that define the composition using structural or measurable technical parameters. Broad claims covering any encapsulated benzoyl peroxide formulation may face substantial prior-art exposure because microencapsulation and topical peroxide delivery were known before Epsolay.

A complete patent-expiration analysis requires a current review of the FDA Orange Book, issued U.S. patents, terminal disclaimers, patent-term adjustments, patent-term restoration, and litigation records. The FDA Drugs@FDA record identifies Epsolay under NDA 213662, but a commercial diligence review should not treat the FDA approval date as the patent-expiration date.[1]

When does Epsolay lose exclusivity?

Epsolay has multiple forms of exclusivity, and they do not expire at the same time.

Exclusivity type	Epsolay position
Active-ingredient exclusivity	No meaningful new-chemical-entity protection for benzoyl peroxide
FDA approval exclusivity	Product-specific exclusivity depends on the NDA and approval designation
Formulation patent protection	Potentially more important than active-ingredient exclusivity
Method-of-use protection	May cover rosacea treatment claims
Trademark protection	Epsolay brand protection continues independently of patents
Regulatory exclusivity for generics	Depends on the ANDA pathway and listed patents

Epsolay was approved on April 25, 2022.[1] Because benzoyl peroxide is not a new chemical entity, the product does not receive five-year NCE exclusivity. A topical generic applicant may pursue an abbreviated new drug application if it can demonstrate pharmaceutical equivalence, bioequivalence or an accepted alternative, and compliance with applicable patent certifications.

The practical loss-of-exclusivity date will depend on the latest enforceable formulation or method-of-use patent, not merely the end of FDA regulatory exclusivity.

What is the Orange Book status of Epsolay?

Epsolay is approved under NDA 213662. Orange Book treatment for topical products can be commercially significant because listed patents may require an ANDA applicant to submit Paragraph IV certifications or wait for listed patent expiration.

The key diligence questions are:

• Which patents are listed against NDA 213662?
• Do the listed patents claim the cream, microspheres, benzoyl peroxide loading, or method of treatment?
• Are any patents subject to pediatric extensions?
• Have any listed patents been delisted, challenged, or withdrawn?
• Does the proposed generic product fall within each asserted claim?
• Does the applicant need to provide a Paragraph IV notice to Galderma or an affiliated patent holder?

A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. If the patent holder brings suit within the statutory period, FDA approval may be stayed for up to 30 months, subject to court decisions and statutory exceptions.[3]

What generic entry risks exist for Epsolay?

Generic entry risk is moderate to high for the active ingredient but lower for the proprietary delivery system.

Active ingredient risk

Benzoyl peroxide is widely available and has a long record of topical use. A competitor can source the active ingredient from multiple manufacturers and develop conventional creams, lotions, washes, or gels.

Formulation risk

A direct generic copy of Epsolay must address more difficult technical issues:

• Reproducing the encapsulated active system.
• Demonstrating equivalent release.
• Matching the physical properties of the cream.
• Controlling benzoyl peroxide degradation.
• Establishing comparable product performance.
• Meeting FDA requirements for topical bioequivalence.

A product that uses unencapsulated benzoyl peroxide may be easier to develop but may not qualify as a direct pharmaceutical equivalent to Epsolay. It could instead compete as a different topical product, depending on FDA classification and labeling.

Commercial substitution risk

Dermatologists may substitute a less expensive benzoyl peroxide product if the patient prioritizes price over tolerability. The risk is higher in acne, where numerous nonprescription benzoyl peroxide products are available. The risk is lower in patients with rosacea who have experienced irritation from conventional products and are prescribed Epsolay for its delivery characteristics.

Which companies could challenge Epsolay?

Potential challengers include:

• Generic dermatology companies with topical semisolid manufacturing capacity.
• Specialty pharmaceutical companies focused on rosacea and acne.
• Contract development and manufacturing organizations with encapsulation capability.
• Companies commercializing silica-based or polymer-based controlled-release systems.
• International manufacturers seeking U.S. topical ANDA opportunities.

The most credible challenger would need more than a low-cost benzoyl peroxide supply chain. It would need analytical methods capable of characterizing particle size, encapsulation, active release, and product stability.

Companies with established topical platforms may also pursue a non-infringing alternative based on polymeric microcapsules, lipid particles, nanodispersions, or a different controlled-release vehicle.

What excipient opportunities exist beyond Epsolay?

Epsolay creates opportunities for excipient suppliers and formulation developers in several areas.

Encapsulated active platforms

A supplier that can encapsulate reactive actives at commercial scale could adapt the platform to:

• Retinoids.
• Azelaic acid.
• Salicylic acid.
• Hydroquinone.
• Sulfur.
• Antifungal agents.
• Low-dose corticosteroids.
• Antibiotics with irritation or stability limitations.

The most valuable platforms will provide reproducible loading, scalable manufacturing, low residual solvent levels, and regulatory support.

Irritation-reduction systems

Topical dermatology companies are seeking vehicles that improve tolerability without reducing efficacy. Opportunities include:

• Controlled-release polymer particles.
• Lipid-based carriers.
• Silica or porous mineral particles.
• Film-forming systems.
• Barrier-supporting emulsion systems.
• Water-activity control.
• pH-buffered vehicles.

A supplier that can demonstrate lower transepidermal irritation while maintaining active delivery can command a premium over commodity emulsifiers and thickeners.

Oxidative-stability systems

Benzoyl peroxide creates stability challenges during processing, filling, storage, and application. Excipient suppliers can differentiate through:

• Low-peroxide-reactivity excipients.
• Oxygen and moisture control.
• Protective packaging.
• Stabilized emulsion systems.
• Validated peroxide assay methods.
• Compatibility data with tubes, pumps, and laminated containers.

Packaging is part of the formulation strategy. A chemically compatible tube or airless dispenser can reduce active loss and support longer shelf life.

How does Epsolay compare with conventional benzoyl peroxide products?

Attribute	Epsolay	Conventional benzoyl peroxide cream or gel
Benzoyl peroxide concentration	5%	Commonly 2.5% to 10%
Delivery	Encapsulated or controlled exposure	Directly dispersed active
Primary indication	Inflammatory lesions of rosacea	Mainly acne, depending on product
Prescription status	Prescription	Prescription or nonprescription, depending on product
Irritation strategy	Designed to reduce direct exposure	Often associated with dryness and irritation
Development complexity	High	Low to moderate
Generic substitution	More difficult	Relatively straightforward
Excipient value	High	Usually lower
Manufacturing barrier	Particle and release control	Conventional semisolid processing

Epsolay’s premium depends on whether clinicians and patients recognize a meaningful tolerability benefit. If the benefit is clinically visible, the encapsulation system supports pricing power. If the benefit is not durable or not differentiated in real-world use, low-cost benzoyl peroxide products can pressure demand.

What manufacturing and intellectual-property barriers matter most?

The principal manufacturing barriers are process consistency and analytical control. Encapsulation must remain stable during high-shear mixing, filling, transportation, and consumer application. The manufacturer must control peroxide content without causing premature release or degradation.

Key manufacturing controls include:

• Raw-material particle-size specifications.
• Encapsulation yield.
• Microsphere integrity.
• Mixing energy.
• Temperature exposure.
• Water content.
• Oxygen exposure.
• Fill-weight uniformity.
• Container closure integrity.
• In-use stability.

The principal intellectual-property barrier is the combination of composition claims and process claims. A competitor may avoid a composition claim but infringe a manufacturing claim, or produce a non-infringing composition that has difficulty meeting the required clinical and regulatory performance.

What is the revenue exposure and commercial outlook?

Epsolay’s revenue exposure is concentrated in prescription dermatology, particularly rosacea treatment. Commercial performance is influenced by:

• Number of diagnosed rosacea patients.
• Dermatologist prescribing behavior.
• Insurance coverage and copay levels.
• Prior-authorization requirements.
• Availability of generic benzoyl peroxide alternatives.
• Patient persistence after irritation or treatment failure.
• Galderma’s ability to expand the product’s prescriber base.

The product has a relatively narrow initial indication but a formulation platform with broader strategic value. Galderma can use the delivery technology to support lifecycle management, line extensions, combination products, and additional dermatology indications, subject to clinical and regulatory requirements.

Key Takeaways

• Epsolay is a prescription 5% benzoyl peroxide cream approved for inflammatory lesions of rosacea.
• Its commercial differentiation comes from encapsulated or controlled-release delivery rather than from a novel active ingredient.
• The main excipients support particle dispersion, rheology, emulsion stability, preservation, and skin feel.
• Generic risk is high for conventional benzoyl peroxide products but lower for a technically equivalent encapsulated formulation.
• The most valuable patent claims are likely to involve microsphere composition, release behavior, manufacturing processes, and rosacea treatment methods.
• Excipient suppliers can pursue adjacent opportunities in irritation reduction, controlled release, oxidative stability, and dermatology delivery platforms.
• The commercial strength of Epsolay depends on clinical tolerability, reimbursement, patent scope, and the difficulty of reproducing its delivery system.

FAQs

Is Epsolay a new chemical entity?

No. Epsolay contains benzoyl peroxide, an established active ingredient. Its differentiation is based on formulation and delivery technology.

Can a generic use the same benzoyl peroxide concentration as Epsolay?

Yes, a generic could use 5% benzoyl peroxide, but matching Epsolay may require equivalent formulation performance, release characteristics, and regulatory evidence.

Are Epsolay’s excipients individually novel?

The listed excipients are generally established pharmaceutical ingredients. The commercial protection is more likely to arise from their combination with encapsulated benzoyl peroxide and the resulting product characteristics.

Could Epsolay technology be used for acne products?

Potentially. The same delivery principles could be applied to acne actives, but a new indication, labeling, formulation, and clinical-development strategy would be required.

Does Epsolay have biosimilar risk?

No. Biosimilar regulations apply to biological products. Epsolay is a nonbiological topical drug. Its competitive risk comes from generic and alternative topical products.

References

1. U.S. Food and Drug Administration. (2022). Epsolay (benzoyl peroxide) cream, 5%: Approval letter and prescribing information, NDA 213662.
2. U.S. Food and Drug Administration. (2022). Epsolay prescribing information.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.